Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Claria Medical secures FDA De Novo classification for hysterectomy device
Claria Medical has secured De Novo classification and marketing authorisation from the US Food and Drug Administration (FDA) for its …
-
First participant dosed in Ionis’ Phase I-II ASCEND study
Ionis Pharmaceuticals has dosed the first participant in its Phase I-II ASCEND trial evaluating ION337, an investigational ribonucleic acid (RNA)-targeted …
-
Cellares and Sonoma partner to automate cell therapy manufacturing
Cellares and Sonoma Biotherapeutics have entered a collaboration to automate the manufacturing of the latter’s lead cell therapy programme, SBT-77-7101, …
-
Virax Biolabs enters immune profiling product supply deal with Fosun
Virax Biolabs Group subsidiary Virax Biolabs (UK) has signed an exclusive commercial supply agreement with Fosun Diagnostics for its research-use-only …
-
Novo Nordisk reports Phase III FRONTIER4 study results for denecimig
Novo Nordisk has reported positive results from the ongoing Phase III FRONTIER4 extension trial, assessing the long-term safety and efficacy …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Cellares and Sonoma partner to automate cell therapy manufacturing
Cellares and Sonoma Biotherapeutics have entered a collaboration to automate the manufacturing of the latter’s lead cell therapy programme, SBT-77-7101, …
-
Virax Biolabs enters immune profiling product supply deal with Fosun
Virax Biolabs Group subsidiary Virax Biolabs (UK) has signed an exclusive commercial supply agreement with Fosun Diagnostics for its research-use-only …
-
Novo Nordisk reports Phase III FRONTIER4 study results for denecimig
Novo Nordisk has reported positive results from the ongoing Phase III FRONTIER4 extension trial, assessing the long-term safety and efficacy …
-
FDA approves MSD’s Keytruda combinations for MIBC
The US Food and Drug Administration (FDA) has approved two of Merck & Co’s (MSD) Keytruda (pembrolizumab) and Keytruda Qlex …
-
TRiCares begins US IDE pivotal trial of TTVR system
TRiCares SAS has enrolled and treated the first patient in its TRICURE US IDE pivotal study of the Topaz transcatheter …
-
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial
Quoin Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application …
-
Apertura and NIH institutes to test gene therapy for NPC1
Apertura has entered a cooperative research and development agreement (CRADA) with various NIH institutes for a gene therapy to treat …
-
Philips expands ultrasound portfolio with AI-driven Alturion
Philips has expanded its ultrasound portfolio with the launch of the Alturion system, which features AI-powered workflows and is intended …
-
First patient receives Forzinity in Mighty Therapeutics’ Phase IV study
Mighty Therapeutics has dosed the first patient in 4TAZPower, its global Phase IV confirmatory study assessing Forzinity (elamipretide) injection in …
-
Evogene and Tel Aviv University launch drug discovery initiative
Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the …
